Novo Nordisk's shares tumbled over 5% in intraday trading on Friday, as the company's blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic landed on Medicare's list of drugs facing price negotiations, potentially leading to significant price cuts starting in 2027. This development came amid growing competition from Eli Lilly's rival drugs, putting pressure on Novo Nordisk's dominant position in the obesity and diabetes markets.
While Novo Nordisk reported positive results from a Phase 3b trial showing that a higher 7.2mg dose of Wegovy led to an average weight loss of 20.7% in patients over 72 weeks, this news was overshadowed by the Medicare pricing announcement. The trial data, though encouraging, failed to alleviate investor concerns about the potential impact of the upcoming price negotiations and intensifying competition from Eli Lilly's offerings.
Analysts and experts highlighted that the Medicare price negotiations could result in substantial savings for the government healthcare program and patients, potentially denting Novo Nordisk's sales growth for its flagship products. However, the company's semaglutide drugs are still expected to see robust global sales growth in the coming years, driven by increasing demand for effective weight-loss and diabetes treatments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。